Plain-English translation of NCT07202364 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This clinical trial is testing a new medication called , which is a type of antibody-drug conjugate designed to target and attack cancer cells. Researchers want to learn whether is safe and effective for people with advanced solid tumors (like lung, colorectal, or cervical cancer) who have already received one or two rounds of other cancer treatments. The study will also measure how the medication moves through your body and what side effects occur.
Many people with advanced cancers stop responding to standard treatments, and doctors need new options to help them live longer and better. This medication is designed to work differently than treatments people may have already tried, targeting a specific protein called HER3 that appears on cancer cells.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will receive doses of at a clinic or hospital setting as part of either a dose-finding phase (to determine the best dose) or a dose-expansion phase (to test that dose more broadly). You will have regular visits to check your health, blood work, and imaging scans to see how the cancer is responding. The study also includes a test period where doctors will study how the medication behaves in your body and monitor you closely for any side effects.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
MediLink Therapeutics (Suzhou) Co., Ltd.
Enrollment target
~100 participants
Started
August 2025
Primary completion
August 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in March 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
yongchang zhang, Ph.D.
MediLink Therapeutics (Suzhou) Co., Ltd.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.